Author

OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner

AddThis Feed Button

Calendar

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended primarily for other attorneys. Orange Book Blog is not edited by McDonnell Boehnen Hulbert & Berghoff LLP ("MBHB") or its clients. Therefore, no part of Orange Book Blog--whether information, commentary, or other--may be attributed to MBHB or its clients. Readers should be aware that MBHB represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MBHB clients. Orange Book Blog will always strive to be unbiased in its reporting. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-08

« No Second Bite at the Apple for Apotex in Acular Litigation; Roche Prevails Again | Main | Pfizer Wins Appeal of Summary Judgment Ruling in Neurontin Case »

September 21, 2007

Pharma News Briefs

  • FDA Law Blog has a great post about a very interesting district court decision concerning Apotex's attempt to market generic Prilosec before AstraZeneca's pediatric exclusivity expires.
  • Congress passed FDA reform legislation this week, albeit without provisions for biosimilars.  (AP article; FDA Law Blog; PhRMA release).
  • In the Pipeline is a great blog by a medicinal chemist.  This week, it has a post about the importance of patents to drug development.
  • Globes reported that according to Merrill Lynch analyst Gregg Gilbert, Wyeth and Teva may settle the Protonix litigation.
  • Pharmalot posted this week on the rising cost of biotech drugs to big pharma.
  • Spicy IP has an interesting post this week on Indian pharmaceutical lifecycle management.

Posted by Aaron Barkoff in Paragraph IV Litigation, Pediatric Exclusivity, Pharma Business News |

Comments

Post a comment

Comments are moderated, and will not appear on this weblog until the author has approved them.